USP and Russia Make Headway on Improving Drug Quality - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP and Russia Make Headway on Improving Drug Quality


ePT--the Electronic Newsletter of Pharmaceutical Technology

In April 2009, the US Pharmacopeial Convention (USP) and the Russian Federation’s regulatory agency, Roszdravnadzor, signed a memorandum of understanding to work toward protecting and improving the quality of medicines worldwide. Last week, USP and the Ukraine Scientific Pharmacopoeial Centre for the Quality of Medicines agreed to share standards for the quality, purity, strength, and identity of medicines. The Ukrainian center will have a five-year, renewable right to include written standards (as written or modified) from the US Pharmacopeia–National Formulary (USP–NF) in its own pharmacopoeia and companion journal, Pharmacom.

“This agreement is a milestone in helping to promote public health internationally. The scientific exchange represented by the agreement with the Centre will benefit not only the citizens of the Ukraine, but also Ukrainian manufacturers wishing to export to other countries,” said USP chief executive officer Roger Williams in a press release. “USP will benefit from the experience of the Centre’s scientists, which in turn contributes to the strength of the standards published in the USP–NF.”

The Ukrainian center also will explore opportunities to use USP’s accompanying reference standards to help evaluate drug quality and identity, according to the release.

Also last week, USP announced that it had completed a series of eight drug quality courses at Moscow’s Scientific Center for Expertise of Medical Products as part of ongoing collaborative efforts.

The original MOU from April 2009 called for USP and Roszdravnadzor to increase working relationships by exchanging scientific staff, facilitating the exchange of information, developing and using reference materials, and establishing third-party certification programs to allow for the review, testing, and auditing of drug manufacturers in the two countries.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here